Growth Metrics

Core Scientific (CORZ) Cash from Financing Activities (2021 - 2026)

Core Scientific has reported Cash from Financing Activities over the past 6 years, most recently at $971.4 million for Q1 2026.

  • Quarterly results put Cash from Financing Activities at $971.4 million for Q1 2026, up 23239.16% from a year ago — trailing twelve months through Mar 2026 was $912.5 million (up 19.9% YoY), and the annual figure for FY2025 was -$63.1 million, down 107.7%.
  • Cash from Financing Activities reached $971.4 million in Q1 2026 per CORZ's latest filing, up from -$21.8 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $971.4 million in Q1 2026 and bottomed at -$45.1 million in Q3 2022.
  • Median Cash from Financing Activities over the past 5 years was -$4.2 million (2025), compared with a mean of $117.0 million.
  • The largest annual shift saw Cash from Financing Activities tumbled 148.04% in 2023 before it skyrocketed 23239.16% in 2026.
  • Over 5 years, Cash from Financing Activities stood at $38.1 million in 2022, then crashed by 148.04% to -$18.3 million in 2023, then skyrocketed by 3369.23% to $598.2 million in 2024, then tumbled by 103.65% to -$21.8 million in 2025, then surged by 4554.25% to $971.4 million in 2026.
  • Business Quant data shows Cash from Financing Activities for CORZ at $971.4 million in Q1 2026, -$21.8 million in Q4 2025, and -$5.3 million in Q3 2025.